SecBot SecBot
SECBOTREPLAY Home › Report › CCCC

CCCC · C4 Therapeutics presented updated Phase 1 data for cemsidomide at EHA…

C4 Therapeutics, Inc. · PRESS-RELEASE filed Jun 11, 2026 at 07:00 ET

At the news

BULLISHIMPACT 6/10

PRESS-RELEASE filed Jun 11, 2026 at 07:00 ET

C4 Therapeutics presented updated Phase 1 data for cemsidomide at EHA 2026, showing a 53% overall response rate at the 100 µg RP2D in heavily pretreated RRMM patients (median 7 prior lines). Responses deepened over time, with MRD negativity achieved in two patients. The data reinforce cemsidomide's differentiated safety profile and support its development as a potential best-in-class IKZF1/3 degrader, though the stock may have limited upside given prior data disclosures and the early-stage nature of the program.

  • 53% ORR at 100 µg RP2D in heavily pretreated RRMM patients (median 7 prior lines)
  • 75% of patients received prior BCMA therapy and prior CAR-T or T-cell engager therapy
  • Responses deepened over time: one patient at 100 µg deepened from PR to sCR, another from PR to VGPR
  • MRD negativity achieved in two patients at 100 µg who achieved sCR and CR

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access